Figure 2.
Interpatient heterogeneity in FL. (A) UMAP representation of dimensionally reduced scRNA-seq data from 20 tumor samples from 10 patients with FL following graph-based clustering. Clusters are assigned to indicated cell types by differentially expressed genes (see also supplemental Figure 1A-B) and cells are colored by patient identity (FL1-FL10). (B) Heatmap representing pathway activity of the top 30 MSigDB “Reactome” gene sets for each patient (FL1-FL10); analysis of variance with Tukey's honestly significant difference P < .05. Selected pathways are highlighted on the right of the heatmap. (C) Oncoprint showing mutations in genes known to be recurrently mutated in B-cell lymphomas, detected by targeted sequencing from archival tumor samples, available for indicated patients. The color coding delineates the type of alteration as indicated in the legend. The number of mutations in each tumor is plotted above.

Interpatient heterogeneity in FL. (A) UMAP representation of dimensionally reduced scRNA-seq data from 20 tumor samples from 10 patients with FL following graph-based clustering. Clusters are assigned to indicated cell types by differentially expressed genes (see also supplemental Figure 1A-B) and cells are colored by patient identity (FL1-FL10). (B) Heatmap representing pathway activity of the top 30 MSigDB “Reactome” gene sets for each patient (FL1-FL10); analysis of variance with Tukey's honestly significant difference P < .05. Selected pathways are highlighted on the right of the heatmap. (C) Oncoprint showing mutations in genes known to be recurrently mutated in B-cell lymphomas, detected by targeted sequencing from archival tumor samples, available for indicated patients. The color coding delineates the type of alteration as indicated in the legend. The number of mutations in each tumor is plotted above.

Close Modal

or Create an Account

Close Modal
Close Modal